- Home
- TLSI vs IGA Comparison
TLSI vs IGA Comparison
Compare TLSI & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- IGA
- Stock Information
- Founded
- TLSI 2010
- IGA 2005
- Country
- TLSI United States
- IGA United States
- Employees
- TLSI N/A
- IGA N/A
- Industry
- TLSI Medical Specialities
- IGA Investment Managers
- Sector
- TLSI Health Care
- IGA Finance
- Exchange
- TLSI Nasdaq
- IGA Nasdaq
- Market Cap
- TLSI 124.9M
- IGA 147.6M
- IPO Year
- TLSI N/A
- IGA N/A
- Fundamental
- Price
- TLSI $3.95
- IGA $9.32
- Analyst Decision
- TLSI Strong Buy
- IGA
- Analyst Count
- TLSI 6
- IGA 0
- Target Price
- TLSI $11.75
- IGA N/A
- AVG Volume (30 Days)
- TLSI 52.7K
- IGA 42.3K
- Earning Date
- TLSI 11-14-2024
- IGA 01-01-0001
- Dividend Yield
- TLSI N/A
- IGA 8.93%
- EPS Growth
- TLSI N/A
- IGA N/A
- EPS
- TLSI N/A
- IGA N/A
- Revenue
- TLSI $26,891,000.00
- IGA N/A
- Revenue This Year
- TLSI $60.97
- IGA N/A
- Revenue Next Year
- TLSI $53.69
- IGA N/A
- P/E Ratio
- TLSI N/A
- IGA N/A
- Revenue Growth
- TLSI 67.90
- IGA N/A
- 52 Week Low
- TLSI $3.50
- IGA $7.77
- 52 Week High
- TLSI $10.42
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- TLSI 46.18
- IGA 39.71
- Support Level
- TLSI $3.76
- IGA $9.34
- Resistance Level
- TLSI $4.17
- IGA $9.45
- Average True Range (ATR)
- TLSI 0.35
- IGA 0.12
- MACD
- TLSI -0.04
- IGA -0.03
- Stochastic Oscillator
- TLSI 33.66
- IGA 13.10
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.